Cancer Treatment Reviews
Volume 31 , Pages 9-18 , 2005

Moving into the future: Treatment of bone metastases and beyond

,Accepted 14 September 2005.

References 

  1. Friedlaender GE, Tross RB, Doganis AC, Kirkwood JM, Baron R. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am. 1984;66(4):602–607
  2. Delmas PD, Fontana A. Bone loss induced by cancer treatment and its management. Eur J Cancer. 1998;34(2):260–262
  3. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–1593
  4. Miller PD. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int. 2001;12(Suppl 3):S3–S10
  5. Finkelstein JS. Osteoporosis. In:  Goldman L,  Ausiello D,  Bennet JC,  Cecil RL editor. Cecil textbook of medicine. 22nd ed.. Philadelphia: WB Saunders Company; 2004;p. 656;1125 ills
  6. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653–661
  7. Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79(3):545–550
  8. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86(4):449–452
  9. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166(5):1724–1728
  10. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser 2003;919:i–x, 1–218, back cover.
  11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62
  12. Thürlimann B. Primary therapy of early breast cancer. In: 9th International Conference. January 26–29, 2005, St. Gallen, Switzerland. Abstracts. Breast 2005;14 Suppl 1:S1–56.
  13. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–1092
  14. Goss PE. NCIC CTG MA.17 Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. In: 2004 ASCO Annual Meeting. Best of Oncology/Society Abstracts; 2004. Available from: http://www.asco.org/ac/.
  15. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittlboeck M, Greil R, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88 Suppl 1(Abstracts of the 27th Annual San Antonio Breast Cancer Symposium. December 8–11, 2004, San Antonio, TX, USA):S7, Abstract 2.
  16. Chen Z, Maricic M, Bassford TL, Ritenbaugh C, Lopez AM, Leboff MS, et al. Increased fracture risk among breast cancer survivors – results from the women’s health initiative. J Bone Miner Res. 2003;18(Suppl 2):S2–S463Abstract 1077
  17. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79(7–8):1179–1181
  18. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57(2):97–99
  19. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219–1222
  20. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–186
  21. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–2367Discussion 2367
  22. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–164
  23. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18(6):1378–1391
  24. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4057
  25. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23(8):1609–1610
  26. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15(3):955–962
  27. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83(8):1561–1566
  28. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92(6):1444–1450
  29. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–955
  30. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75(4):602–605
  31. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicenter trial (ABCSG-12). In: San Antonio Breast Cancer Symposium. San Antonio, TX; 2004.
  32. Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere O, Collette J, et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int. 2001;69(3):130–137
  33. Brufsky A, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): preliminary results of the Z-FAST trial. In: San Antonio Breast Cancer Symposium. San Antonio, TX; 2004.
  34. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol. 2004;46(6):731–739Discussion 739-40
  35. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167(5):1952–1956
  36. Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol. 2005;47(5):575–580Discussion 580-1
  37. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–2012
  38. Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F, Diel IJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a longtime follow-up. J Clin Oncol 2004;22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 529.
  39. Powles T, McCloskey E, Kurkilahti M. Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 2004;22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 528.
  40. Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 2004;22(14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 527.
  41. Clézardin P. Anti-tumor activity of Zoledronic acid. Cancer Treat Rev 2005;31(this issue):S1–S8.
  42. Study Team EAU CRO. ZEUS study: Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients. Eur Urol Today 2004;16(4):6.
  43. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J. 2002;167(10 Suppl):S1–S34
  44. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927–2941

PII: S0305-7372(05)00162-3

doi: 10.1016/j.ctrv.2005.09.003

Cancer Treatment Reviews
Volume 31 , Pages 9-18 , 2005

Article Tools

* Image Usage & Resolution